Our newsroom features all of the latest news, publications and media coverage for the Pediatric Immunotherapy Program.
The University System of Georgia Board of Regents recently approved David C. Hess, MD, David Munn, MD, and Babak Baban, PhD, as the first three Augusta University faculty researchers to be named Regents’ Entrepreneurs for their success in translating research into a commercial setting to improve patient care.
The first in-human study of a new immunotherapy that blocks a natural enzyme that tumors commandeer for their protection was well tolerated by children with relapsed brain tumors and enabled many to have unexpected months of a more normal life, researchers say.
“Baxter loved superheroes because of their superpowers,” said Brook Duddy, Baxter’s mom. “They could do things ordinary people could not do. So, we told him the radiation was turning him into a superhero to fight his cancer.”
They are the littlest patients facing one of life’s biggest battles from a disease that can be deadly. However, children undergoing treatment for brain cancer and other forms of cancer have an ally in their fight.
Pediatric Immunotherapy Program in The News